University of California, San Francisco Logo

University of California, San Francisco | About UCSF | Search UCSF | UCSF Medical Center

Home > Treatment > Interactions
Database of Antiretroviral Drug Interactions

Interactions with Ticagrelor and Antiretrovirals

Antiretroviral (ARV)Dose of ARVDose of TicagrelorEffect on ARV LevelsEffect on Ticagrelor LevelsPotential Clinical EffectsMechanism of InteractionManagement
Atazanavir727
(ATV)(Reyataz)
--- Not studied; may increase effects of ticagrelor Potential for increased risk of bleeding Inhibition of ticagrelor metabolism via CYP3A4

Avoid concomitant use; consider alternative antiplatelet agent

Atazanavir/cobicistat727
(others)(Evotaz)
--- Not studied; may increase effects of ticagrelor Potential for increased risk of bleeding Inhibition of ticagrelor metabolism via CYP3A4

Avoid concomitant use; consider alternative antiplatelet agent

Darunavir727
(DRV)(Prezista)
--- Not studied; may increase effects of ticagrelor Potential for increased risk of bleeding Inhibition of ticagrelor metabolism via CYP3A4

Avoid concomitant use; consider alternative antiplatelet agent

Darunavir/cobicistat727
(Prezcobix)
--- Not studied; may increase effects of ticagrelor Potential for increased risk of bleeding Inhibition of ticagrelor metabolism via CYP3A4

Avoid concomitant use; consider alternative antiplatelet agent

Elvitegravir/cobicistat705
(Genvoya, Stribild)
---Not studied; may increase effects of ticagrelorPotential for increased risk of bleedingInhibition of ticagrelor metabolism via CYP3A4

Avoid concomitant use; consider alternative antiplatelet agent

Antiretroviral (ARV)Dose of ARVDose of TicagrelorEffect on ARV LevelsEffect on Ticagrelor LevelsPotential Clinical EffectsMechanism of InteractionManagement
Elvitegravir/ritonavir-boosted protease inhibitor705
---Not studied; may increase ticagrelor levelsPotential for increased risk of bleedingInhibition of ticagrelor metabolism via CYP3A4

Avoid concomitant use; use alternative antiplatelet agent

Fosamprenavir727
(FPV)(Lexiva)
--- Not studied; may increase effects of ticagrelor Potential for increased risk of bleeding Inhibition of ticagrelor metabolism via CYP3A4

Avoid concomitant use; consider alternative antiplatelet agent

Lopinavir/ritonavir727
(LPV/r)(Kaletra)
--- Not studied; may increase effects of ticagrelor Potential for increased risk of bleeding Inhibition of ticagrelor metabolism via CYP3A4

Avoid concomitant use; consider alternative antiplatelet agent

Ritonavir727
(RTV)(Norvir)
--- Not studied; may increase effects of ticagrelor Potential for increased risk of bleeding Inhibition of ticagrelor metabolism via CYP3A4

Avoid concomitant use; consider alternative antiplatelet agent

Saquinavir727
(SQV)(Fortovase, Invirase)
--- Not studied; may increase effects of ticagrelor Potential for increased risk of bleeding Inhibition of ticagrelor metabolism via CYP3A4

Avoid concomitant use; consider alternative antiplatelet agent

Tipranavir727
(TPV)(Aptivus)
--- Not studied; may increase effects of ticagrelor Potential for increased risk of bleeding-

Avoid concomitant use; consider alternative antiplatelet agent

"-" indicates that there are no data available
 705:Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf.
 727:Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf.